Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158.14 million, down 14% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.Given this perspective, it's time to examine the average forecasts of specific 10x Genomics metrics that are routinely monitored and predicted by Wall Street analysts.The collective assessment of analysts points to an estimated 'Revenues- Consumables' of $128.51 million. The estimate suggests a change of -8.4% year over year.Analysts' assessment points toward 'Revenues- Instruments' reaching $19.02 million. The estimate indicates a change of -50.5% from the prior-year quarter.Based on the collective assessment of analysts, 'Revenues- Services' should arrive at $6.52 million. The estimate points to a change of +23.7% from the year-ago quarter.View all Key Company Metrics for 10x Genomics here>>>Over the past month, 10x Genomics shares have recorded returns of -23.2% versus the Zacks S&P 500 composite's +4.2% change. Based on its Zacks Rank #3 (Hold), TXG will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 10x Genomics (TXG): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks